Inventor
Daniel E. H. Afar
Inventor
Pacific Palisades, CA, US
Overview
Patents· 94 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C07Kprimary
C07KPeptides23%
A61KPreparations for medical, dental or toiletry purposes19%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations18%
G01NInvestigating or analysing materials by determining their chemical or physical properties9%
A01KAnimal husbandry8%
Y02ATechnologies for adaptation to climate change8%
C12NMicroorganisms or enzymes5%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms4%
Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests3%
Y10TTechnical subjects covered by former us classification3%
PatentTitleYear
10,730,953Anti-PD-1 antibodies and their uses20209,914,783'Anti-PD-1 antibodies and their uses'20188,647,826'Nucleic acid and corresponding protein entitled 125P5C8 useful in treatment and detection of cancer'20148,603,477'Use of anti-CS1 antibodies for treatment of rare lymphomas'20138,414,898'Serpentine transmembrane antigens expressed in human cancers and uses thereof'20138,383,777'13-transmembrane protein expressed in prostate cancer'20138,257,708'Antibodies against cancer antigen TMEFF2 and uses thereof'20128,241,626'Serpentine transmembrane antigens expressed in human cancers and uses thereof'20128,173,381'Nucleic acid and corresponding protein entitled 85P1B3 useful in treatment and detection of cancer'20128,101,372'Diagnosis and therapy of cancer using SGP28-related molecules'20128,053,551'Serpentine transmembrane antigens expressed in human cancers and uses therefor'20118,039,603'Nucleic acid and corresponding protein entitled 121P1F1 useful in treatment and detection of cancer'20118,039,000'Nucleic acid and corresponding protein entitled 158P3D2 useful in treatment and detection of cancer'20118,022,174'C-type lectin transmembrane antigen expressed in human prostate cancer and uses therof'20118,013,126'84P2A9: a prostate and testis specific protein highly expressed in prostate cancer'20118,003,758'BPC-1: a secreted brain-specific protein expressed and secreted by prostate and bladder cancer cells'20117,981,624'Methods to detect tumors using 20P1F12/TMPRSS2 expression'20117,968,307'Serpentine transmembrane antigens expressed in human cancers and uses thereof'20117,968,283'Gene expressed in prostate cancer'20117,951,375'Methods of inducing an immune response'20117,947,459'Serpentine transmembrane antigens expressed in human cancers and uses thereof'20117,928,196'Nucleic acid and corresponding protein entitled 125P5C8 useful in treatment and detection of cancer'20117,928,201'Serpentine transmembrane antigens expressed in human cancers and uses thereof'20117,928,212'Gene upregulated in cancers of the prostate'20117,897,740'Secreted protein called 36P6D5 characteristic of tumors'20117,892,548'121P1F1: a tissue specific protein highly expressed in various cancers'20117,858,760'Antibodies to protein expressed in prostate cancer'20107,842,293'Compositions and methods using anti-CS1 antibodies to treat multiple myeloma'20107,834,156'125P5C8: tissue specific protein highly expressed in various cancers'20107,824,678'Antibodies against cancer antigen TMEFF2 and uses thereof'20107,803,916'Gene expressed in prostate cancer'20107,795,391'Protein showing enhanced expression in cancer cells'20107,785,811'BPC-1: a secreted brain-specific protein expressed and secreted by prostate and bladder cancer cells'20107,785,816'Antibodies against cancer antigen TMEFF2 and uses thereof'20107,771,968'Gene upregulated in cancers of the prostate'20107,759,474'Nucleic acid and corresponding protein entitled 125P5C8 useful in treatment and detection of cancer'20107,736,853'Methods of diagnosis of androgen-dependent prostate cancer, prostate cancer undergoing androgen withdrawal, and androgen-independent prostate cancer'20107,736,654'Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers'20107,727,533'Serpentine transmembrane antigens expressed in human cancers and uses thereof'20107,674,883'Antibodies against cancer antigen TMEFF2 and uses thereof'20107,641,905'Methods of inducing an immune response'20107,642,054'Serpentine transmembrane antigens expressed in human cancers and uses thereof'20107,628,989'Methods of inducing an immune response'20097,611,904'Serpentine transmembrane antigens expressed in human cancers and uses thereof'20097,601,825'Nucleic acid and corresponding protein entitled 121P1F1 useful in treatment and detection of cancer'20097,598,045'C-type LECTIN transmembrane antigen expressed in human prostate cancer and uses thereof'20097,582,448'84P2A9: a prostate and testis specific protein highly expressed in prostate cancer'20097,575,749'Serpentine transmembrane antigens expressed in human cancers and uses thereof'20097,569,356'Diagnosis and therapy of cancer using SGP28-related molecules'20097,534,417'103P2D6: tissue specific protein highly expressed in various cancers'20097,510,840'Method of inhibiting growth or survival of a cell by providing an anti-108P5H8 antibody'20097,510,855'84P2A9: a prostate and testis specific protein highly expressed in prostate cancer'20097,507,541'36P6D5: secreted tumor antigen'20097,501,502'Nucleic acid and corresponding protein entitled 85P1B3 useful in treatment and detection of cancer'20097,488,479'Nucleic acid and corresponding protein entitled 125P5C8 useful in treatment and detection of cancer'20097,485,299'Serpentine transmembrane antigens expressed in human cancers and uses thereof'20097,459,539'Antibody that binds zinc transporter protein 108P5H8'20087,455,991'Serpentine transmembrane antigens expressed in human cancers and uses thereof'20087,432,346'Gene expressed in prostate cancer'20087,351,583'Antibodies to G protein-coupled receptor'20087,319,006'Serpentine transmembrane antigens expressed in human cancers and uses thereof'20087,309,585'121P1F1: a tissue specific protein highly expressed in various cancers'20077,306,796'13-transmembrane protein expressed in prostate cancer'20077,288,248'Antibodies against cancer antigen TMEFF2 and uses thereof'20077,271,240'125P5C8: a tissue specific protein highly expressed in various cancers'20077,227,008'13-transmembrane protein expressed in prostate cancer'20077,223,542'36P6D5: secreted tumor antigen'20077,220,823'Transmembrane protein expressed in prostate and other cancers'20077,217,799'Antibodies that recognize the 85P1B3 protein useful in treatment and detection of cancer'20077,208,280'Nucleic acid and corresponding protein entitled 101P3A41 useful in treatment and detection of cancer'20077,199,220'103P2D6: tissue specific protein highly expressed in various cancers'20077,172,898'103P2D6: tissue specific protein highly expressed in various cancers'20077,166,714'Serpentine transmembrane antigens expressed in human cancers and uses thereof'20077,153,940'C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof'20067,148,337'C-type LECTIN transmembrane antigen expressed in human prostate cancer and uses thereof'20067,087,718'C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof'20067,053,186'Antibodies immunospecific for STEAP1'20067,037,667'Tumor antigen useful in diagnosis and therapy of prostate and colon cancer'20067,008,779'PHELIX: a testis-specific protein expressed in cancer'20066,943,235'Transmembrane protein expressed in prostate cancer'20056,924,358'121P1F1: a tissue specific protein highly expressed in various cancers'20056,893,818'Gene upregulated in cancers of the prostate'20056,887,975'Peptides derived from STEAP1'20056,863,892'Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers'20056,838,258'G protein-coupled receptor up-regulated in prostate cancer and uses thereof'20056,835,822'Diagnosis and therapy of cancer using SGP28-related molecules'20046,833,438'Serpentine transmembrane antigens expressed in human cancers and uses thereof'20046,790,631'G protein-coupled receptor up-regulated in prostate cancer and uses thereof'20046,652,859'PTANS: testis specific proteins expressed in prostate cancer'20036,602,501'C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof'20036,566,078'36P6D5: secreted tumor antigen'20036,509,458'Gene expressed in prostate cancer'20036,329,503'Serpentine transmembrane antigens expressed in human cancers and uses thereof'20016,277,972'BPC-1: a secreted brain-specific protein expressed and secreted by prostate and bladder cancer cells'2001Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2001–2014Patents assigned to AGENSYS INC (81)· patent assignee history
2001–2013Based in Pacific Palisades, CA, US· patent location history
2003–2012Based in Brisbane, CA, US· patent location history
2009–2012Based in Fremont, CA, US· patent location history
2010Patents assigned to FACET BIOTECH CORP (4)· patent assignee history
2010Based in Mountain View, CA, US· patent location history
2012–2014Patents assigned to HUBERT RENE S (6)· patent assignee history
2012–2014Patents assigned to RAITANO ARTHUR B (6)· patent assignee history
2012–2014Patents assigned to FARIS MARY (4)· patent assignee history
2018–2020Based in Los Altos Hills, CA, US· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| AGENSYS INC | 81 | 2001–2014 |
| HUBERT RENE S | 6 | 2012–2014 |
| RAITANO ARTHUR B | 6 | 2012–2014 |
| FACET BIOTECH CORP | 4 | 2010 |
| FARIS MARY | 4 | 2012–2014 |
Locations
| Location | Patents | Span |
|---|---|---|
| Pacific Palisades, California, US | 39 | 2001–2013 |
| Brisbane, California, US | 27 | 2003–2012 |
| Fremont, California, US | 21 | 2009–2012 |
| Mountain View, California, US | 3 | 2010 |
| Los Altos Hills, California, US | 2 | 2018–2020 |